H

Hospital Italiano de La Plata | Clinical Research Department

Research site
(Unclaimed)
Location
Calle 50, 1741, La Plata, Buenos Aires, Argentina
Site insights

Top conditions

Leukemia (6 trials)

Ulcer (5 trials)

Plasma Cell Cancer (4 trials)

Colitis (4 trials)

Multiple Myeloma (4 trials)

Top treatments

Bosutinib
GDC-0853
Daratumumab
Bemarituzumab
Litifilimab
BIIB059
Linagliptin
Ziltivekimab
S42909
Elafibranor

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

24 of 51
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.

Enrolling
Solid Tumors
Drug: Bemarituzumab

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered...

Enrolling
Dermatomyositis
Drug: Placebo
Drug: GLPG3667

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Etrasimod
Drug: Placebo

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Enrolling
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Other: Placebo
Drug: Guselkumab Dose 1

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo,...

Active, not recruiting
Autologous Stem Cell Transplant
Multiple Myeloma
Drug: Ixazomib Citrate
Drug: Placebo

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA...

Active, not recruiting
Psoriatic Arthritis
Drug: Apremilast
Other: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Litifilimab
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Enrolling
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment in 2 months
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclo...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

Primary objective:- To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitali...

Enrolling
Infectious Pneumonia
Severe COVID-19
Other: Placebo
Drug: Reparixin

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

Trial sponsors

Pfizer logo

Pfizer (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems